These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22101246)

  • 1. Potent anti-respiratory syncytial virus activity of a cholestanol-sulfated tetrasaccharide conjugate.
    Lundin A; Bergström T; Andrighetti-Fröhner CR; Bendrioua L; Ferro V; Trybala E
    Antiviral Res; 2012 Jan; 93(1):101-9. PubMed ID: 22101246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles.
    Said JS; Trybala E; Görander S; Ekblad M; Liljeqvist JÅ; Jennische E; Lange S; Bergström T
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1049-57. PubMed ID: 26643323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus.
    Ekblad M; Adamiak B; Bergstrom T; Johnstone KD; Karoli T; Liu L; Ferro V; Trybala E
    Antiviral Res; 2010 May; 86(2):196-203. PubMed ID: 20176055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two novel fusion inhibitors of human respiratory syncytial virus.
    Lundin A; Bergström T; Bendrioua L; Kann N; Adamiak B; Trybala E
    Antiviral Res; 2010 Dec; 88(3):317-24. PubMed ID: 20965215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action.
    Sudo K; Miyazaki Y; Kojima N; Kobayashi M; Suzuki H; Shintani M; Shimizu Y
    Antiviral Res; 2005 Feb; 65(2):125-31. PubMed ID: 15708639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity and mode of action of caffeoylquinic acids from Schefflera heptaphylla (L.) Frodin.
    Li Y; But PP; Ooi VE
    Antiviral Res; 2005 Oct; 68(1):1-9. PubMed ID: 16140400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells.
    Lundin A; Bergström T; Trybala E
    Methods Mol Biol; 2013; 1030():345-63. PubMed ID: 23821281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin.
    Xu Z; Kuang M; Okicki JR; Cramer H; Chaudhary N
    Antiviral Res; 2004 Mar; 61(3):195-206. PubMed ID: 15168801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
    Elliott MB; Tebbey PW; Pryharski KS; Scheuer CA; Laughlin TS; Hancock GE
    J Med Virol; 2004 Jun; 73(2):300-8. PubMed ID: 15122808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA.
    Atreya PL; Kulkarni S
    Virology; 1999 Sep; 261(2):227-41. PubMed ID: 10497108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipophile-conjugated sulfated oligosaccharides as novel microbicides against HIV-1.
    Said J; Trybala E; Andersson E; Johnstone K; Liu L; Wimmer N; Ferro V; Bergström T
    Antiviral Res; 2010 Jun; 86(3):286-95. PubMed ID: 20307578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad spectrum antiviral fractions from the lichen Ramalina farinacea (L.) Ach.
    Esimone CO; Grunwald T; Nworu CS; Kuate S; Proksch P; Uberla K
    Chemotherapy; 2009; 55(2):119-26. PubMed ID: 19155620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activities of diarylheptanoids isolated from Alpinia officinarum against respiratory syncytial virus, poliovirus, measles virus, and herpes simplex virus type 1 in vitro.
    Konno K; Sawamura R; Sun Y; Yasukawa K; Shimizu T; Watanabe W; Kato M; Yamamoto R; Kurokawa M
    Nat Prod Commun; 2011 Dec; 6(12):1881-4. PubMed ID: 22312729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel inhibitor of respiratory syncytial virus isolated from ethnobotanicals.
    Ojwang JO; Wang YH; Wyde PR; Fischer NH; Schuehly W; Appleman JR; Hinds S; Shimasaki CD
    Antiviral Res; 2005 Dec; 68(3):163-72. PubMed ID: 16280176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells.
    Iesato K; Tatsumi K; Saito K; Ogasawara T; Sakao S; Tada Y; Kasahara Y; Kurosu K; Tanabe N; Takiguchi Y; Kuriyama T; Shirasawa H
    Respiration; 2008; 76(4):434-41. PubMed ID: 18728351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A respiratory syncytial virus isolate enables the testing of virucidal products.
    Thevenin T; Lobert PE; Dewilde A; Hober D
    Int J Hyg Environ Health; 2012 Apr; 215(3):293-6. PubMed ID: 22079427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate.
    Henderson EA; Alber DG; Baxter RC; Bithell SK; Budworth J; Carter MC; Chubb A; Cockerill GS; Dowdell VC; Fraser IJ; Harris RA; Keegan SJ; Kelsey RD; Lumley JA; Stables JN; Weerasekera N; Wilson LJ; Powell KL
    J Med Chem; 2007 Apr; 50(7):1685-92. PubMed ID: 17341059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.
    Budge PJ; Li Y; Beeler JA; Graham BS
    J Virol; 2004 May; 78(10):5015-22. PubMed ID: 15113882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses.
    Budge PJ; Graham BS
    J Antimicrob Chemother; 2004 Aug; 54(2):299-302. PubMed ID: 15254023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.